Catheter Precision, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Catheter Precision, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $442.0K | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $14.0K | Apr 1, 2024 |
| FY2020 | Dec 31, 2020 | $4.41M | Mar 17, 2021 |
| FY2020 | Dec 31, 2019 | $7.20M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $6.26M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $5.87M | Mar 15, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $819.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $420.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $442.0K | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | $14.0K | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $22.0K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $259.0K | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $7.20M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $6.26M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $5.87M | Mar 15, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $756.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $378.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $412.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($147.0K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($1.54M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($1.91M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($1.65M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $2.05M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $1.71M | Mar 15, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.18M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($16.64M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($70.57M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($26.87M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($25.07M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($36.05M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($56.96M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($30.83M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($17.77M) | Mar 15, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.14M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($11.24M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($78.12M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($26.96M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($29.27M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($35.40M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($57.73M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($31.16M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($17.76M) | Mar 15, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $272.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $475.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.39M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $12.25M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $8.96M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $4.53M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $2.78M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $4.52M | Mar 15, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.08M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $11.35M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $17.12M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $16.25M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $15.48M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $24.53M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $51.55M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $30.44M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $14.95M | Mar 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.30M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($9.27M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($20.62M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($22.57M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($27.63M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($28.30M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($33.17M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($18.51M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($5.52M) | Mar 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $67.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $76.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $17.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $265.0K | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $67.0K | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $268.0K | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $582.0K | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $547.0K | Mar 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.86M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $27.77M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $30.74M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $16.84M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $21.04M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $33.44M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $44.08M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $74.04M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $11.27M | Mar 15, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.21M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $16.01M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $9.54M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $7.58M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $7.37M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $12.29M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $10.93M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $7.33M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $18.88M | Mar 15, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.05M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $11.76M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $21.19M | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $9.26M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $13.67M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $21.15M | Mar 28, 2023 |
| FY2021 | Dec 31, 2019 | $33.15M | Mar 24, 2022 |
| FY2020 | Dec 31, 2018 | $66.73M | Mar 17, 2021 |
| FY2019 | Dec 31, 2017 | ($7.62M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2016 | ($380.0K) | Mar 15, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2023 | $0 | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | $0 | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $0 | Apr 1, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($309.54M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($292.35M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($275.71M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($205.14M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($178.27M) | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | ($153.20M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($117.16M) | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | ($60.22M) | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | ($29.39M) | Mar 15, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $88.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.87M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.57M | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | $15.86M | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | $15.05M | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | $23.91M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $14.58M | Mar 17, 2021 |
| FY2019 | Dec 31, 2018 | $64.32M | Mar 11, 2020 |
| FY2018 | Dec 31, 2017 | $8.24M | Mar 15, 2019 |
| FY2018 | Dec 31, 2016 | $3.92M | Mar 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.08M | Mar 31, 2026 |
| FY2019 | Dec 31, 2019 | $558.0K | Mar 11, 2020 |
| FY2018 | Dec 31, 2018 | $850.0K | Mar 15, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (15) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (126) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (129) | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | (25) | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | (248) | Mar 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | (25) | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | (248) | Mar 28, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.74M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 421,296 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 702,662 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 2.16M | Apr 1, 2024 |
| FY2022 | Oct 3, 2022 | 1.40M | Mar 28, 2023 |
| FY2022 | Sep 20, 2022 | 68.20M | Mar 28, 2023 |
| FY2022 | Dec 31, 2021 | 140,000 | Mar 28, 2023 |
| FY2021 | Dec 31, 2020 | 3,189 | Mar 24, 2022 |
| FY2020 | Nov 16, 2020 | 2.90M | Mar 17, 2021 |
| FY2020 | Nov 15, 2020 | 73.00M | Mar 17, 2021 |